Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jiqing Ye has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Integrated Machine Learning and Structure-Based Virtual Screening Identifies Novel Myeloperoxidase Inhibitors with Cardioprotective Activity

    by Feng Gao, Chu Chen, Ruyue Yang, Haichen Xu, Qianqian Dong, Qiqi Han, Xiaowen Feng, Jiqing Ye

    Myeloperoxidase (MPO) has emerged as a promising therapeutic target for heart failure (HF) because of its pathogenic roles in oxidative stress, inflammation, and myocardial fibrosis. However, the clinical development of MPO inhibitors remains limited, and most candidates have failed in advanced trials. Here, we report the discovery of novel MPO inhibitors through an integrated computational pipeline combining machine-learning-based virtual screening with structure-based consensus docking. This approach screened ~3.1 million compounds and yielded 25 candidates for experimental evaluation. Among these, compound 16 exhibited potent MPO inhibition (IC50 = 0.297 ± 0.097 μM) and conferred significant cardioprotection in H9c2 cells subjected to oxygen-glucose deprivation, preserving cell viability to 66.19% at 25 μM. Mechanistic investigations revealed that compound 16 reduced lactate dehydrogenase release, decreased reactive oxygen species accumulation, and suppressed hypoxia/reoxygenation-induced α-SMA upregulation in a neutrophil-conditioned medium model. In addition, molecular dynamics simulations and MM-PBSA/MM-GBSA calculations suggested stable binding to MPO, primarily through π-stacking with the heme prosthetic group and hydrophobic contacts with key active-site residues. Compound 16 showed favorable predicted permeability and low predicted hERG liability, but poor metabolic stability in rat liver microsomes (T1/2 = 1.34 min), indicating that metabolic optimization is required. Collectively, this study establishes a computationally efficient strategy for MPO inhibitor discovery and identifies compound 16 as an MPO inhibitor that protects cardiomyocytes in vitro, providing a starting point for future in vivo studies aimed at heart failure therapy.

  • A Kinetic Origin of Vps34-IN-3 Selectivity for VPS34 over PI3Kα Revealed by Supervised Molecular Dynamics and Potential of Mean Force Analysis

    by Liang Yu, Qianqian Dong, Qiqi Han, Si Dong, Xiaoshuai Cheng, Jiabin Li, Jiqing Ye

    The rational design of selective kinase inhibitors is hampered by the conserved ATP-binding pockets. Vps34-IN-3, a potent VPS34 inhibitor developed by Genentech, Inc., showed ∼95-fold selectivity over the closely related PI3Kα, yet the atomic-level mechanism underlying this selectivity remains unclear. Here, we combined supervised molecular dynamics (SuMD) and potential of mean force (PMF) analysis to reconstruct the complete binding and unbinding pathways of Vps34-IN-3 to both targets. Our calculations revealed that selectivity arose primarily from a dramatically higher dissociation barrier for VPS34, leading to a prolonged residence time on the intended target. In VPS34, a persistent hydrogen bond with Ile685 and a hydrophobic socket beneath the P-loop acted as a structural latch, raising the unbinding barrier to 6.37 kcal/mol. In contrast, the more open PI3Kα pocket presented a lower barrier of 3.71 kcal/mol. The computed residence-time ratio (∼80-fold) was strongly consistent with the experimentally measured selectivity (∼95-fold based on IC50 values), suggesting that the selectivity of Vps34-IN-3 is primarily kinetic in origin. Our integrated SuMD/PMF framework thus established a kinetic basis for inhibitor selectivity and provided a quantitative, transferable approach for predicting residence time in drug discovery.

  • Understanding the structural stability and plasticity of VPS34 protein determined by selective/nonselective inhibitors: insights from molecular dynamics simulations

    by Liang Yu, Chu Chen, Qianqian Dong, Fangxin Luo, Jiabing Li, Jiqing Ye

    Vacuolar sorting protein 34 (VPS34), a sole member of class III phosphoinositide 3-kinase (PI3K), regulates critical cellular processes, such as endosomal trafficking and autophagosome biogenesis, making it a promising target for diseases such as cancer and neurodegenerative disorders. However, developing highly selective inhibitors for VPS34 is challenging due to the structural conservation of its ATP-binding site across PI3Ks. In this study, to elucidate the structural dynamics of selective ligand recognition, we performed molecular dynamics (MD) simulations to explore the conformational landscape of VPS34 in both its apo state and in complex with selective/nonselective ligands. MD simulations and trajectory analysis showed that the whole structural stability and rigidity of VPS34 were increased in the presence of selective ligands. Moreover, pocket dynamical analysis demonstrated that the binding pockets were more stable and conserved upon binding to selective ligands. Furthermore, our results indicated that the ligand selectivity was not determined by the ligand’s ability to enter the pocket or residue-level interaction energetics. Overall, these results suggested that the ligand selectivity arose from limiting intrinsic dynamics of VPS34 and thereof increasing its rigidity. These findings offer a new mechanistic framework and structural criteria for the rational design and screening of next-generation selective VPS34 inhibitors.


  • Virtual Screening and Biological Evaluation of Natural Products as Novel VPS34 Inhibitors that Modulate Autophagy

    by Xiaowen Feng, Baoming Wu, Hanyang Xu, Chu Chen, Jiqing Ye

    VPS34 is a sole member of class III phosphoinositide 3‐kinase involved in endosomal trafficking and autophagosome formation, making it an interesting target for cancer treatment. Here, we investigated 5,774 natural products using structure‐based virtual screening against human VPS34. 10 natural products identified by virtual screening were purchased and tested in VPS34 ADP‐Glo assay, yielding several potential VPS34 inhibitors. Amongst, Salvianolic acid A (4) and Ellagic acid (8) inhibited VPS34 with IC50 values of 2.46 and 3.12 μM, respectively, more potent than the positivity control 3‐MA. Moreover, in vitro assays demonstrated that both of the compounds suppressed vesicle trafficking in cell‐based assay. Significantly, Salvianolic acid (4) effectively prevented autophagy in Hela cells induced either by starvation or Rapamycin, an mTOR inhibitor. In addition, in silico analysis was done to elucidate the binding mechanisms of the ligand in complex with VPS34. Overall, this study highlights the efficacy of structure‐based virtual screening and presents several natural products as VPS34 inhibitors that modulate autophagy.


  • Open Access

    Mapping the Binding Hotspots and Transient Binding Pockets on V-Domain Immunoglobulin Suppressor of T Cell Activation Protein Surface

    by Bingjie Li, Lixiu Xu, Chu Chen, Jiqing Ye

    V-domain immunoglobulin suppressor of T cell activation (VISTA), an inhibitory immune checkpoint present on both immune and tumor cells, has emerged as a highly promising target for cancer therapy due to its potential to overcome resistance encountered with existing immune checkpoint treatments. VSIG-3 is determined as an inhibitory ligand for VISTA, leading to the suppression of T cell proliferation. However, hotspots between VISTA/VSIG-3 protein-protein interaction remain ambiguous, mainly attributed to the lack of the structure of the VISTA/VSIG-3 complex. Therefore, in this study, in order to determine the energetic contributions of the interfacial residues on VISTA, we first constructed VISTA/VSIG-3 complex models by the protein docking method, followed by molecular dynamics simulations, binding free-energy decomposition, and alanine scanning. Results suggested that the putative hotspots in VISTA comprise residues His32, Tyr37, Thr35, Glu47, Val48, Gln49, Glu53, Arg54, Gln73, His122, and His126. Moreover, the distribution of the hotspots was clustered into two regions (hot regions I and II), and by using the TRAPP tool, transient subpockets within the hot regions were identified. Furthermore, conformational states of the binding pockets exhibiting druggability scores higher than those observed in the crystal structure were found. Overall, we hope that the findings outlined in this study can be used to facilitate the development of inhibitors targeting the VISTA/VSIG-3 immune checkpoint pathway in the future.


  • Inhibition of bacterial RNA polymerase function and protein–protein interactions: a promising approach for next-generation antibacterial therapeutics

    by Jiqing Ye, Cheuk Hei Kan, Xiao Yang, Cong Ma

    The increasing prevalence of multidrug-resistant pathogens necessitates the urgent development of new antimicrobial agents with innovative modes of action for the next generation of antimicrobial therapy.


  • Open Access

    Ligand-Based Drug Design of Novel Antimicrobials against Staphylococcus aureus by Targeting Bacterial Transcription

    by Jiqing Ye, Xiao Yang, Cong Ma

    Staphylococcus aureus is a common human commensal pathogen that causes a wide range of infectious diseases. Due to the generation of antimicrobial resistance, the pathogen becomes resistant to more and more antibiotics, resulting in methicillin-resistant S. aureus (MRSA) and even multidrug-resistant S. aureus (MDRSA), namely ‘superbugs’. This situation highlights the urgent need for novel antimicrobials. Bacterial transcription, which is responsible for bacterial RNA synthesis, is a valid but underutilized target for developing antimicrobials. Previously, we reported a novel class of antimicrobials, coined nusbiarylins, that inhibited bacterial transcription by interrupting the protein–protein interaction (PPI) between two transcription factors NusB and NusE. In this work, we developed a ligand-based workflow based on the chemical structures of nusbiarylins and their activity against S. aureus. The ligand-based models—including the pharmacophore model, 3D QSAR, AutoQSAR, and ADME/T calculation—were integrated and used in the following virtual screening of the ChemDiv PPI database. As a result, four compounds, including J098-0498, 1067-0401, M013-0558, and F186-026, were identified as potential antimicrobials against S. aureus, with predicted pMIC values ranging from 3.8 to 4.2. The docking study showed that these molecules bound to NusB tightly with the binding free energy ranging from −58 to −66 kcal/mol.


  • Open Access

    QSAR, Docking, and Molecular Dynamics Simulation Studies of Sigmacidins as Antimicrobials against Streptococci

    by Jiqing Ye, Xiao Yang, Cong Ma

    Streptococci are a family of bacterial species significantly affecting human health. In addition, environmental Streptococci represent one of the major causes of diverse livestock diseases. Due to antimicrobial resistance, there is an urgent need for novel antimicrobial agent discovery against Streptococci. We discovered a class of benzoic acid derivatives named sigmacidins inhibiting the bacterial RNA polymerase-σ factor interaction and demonstrating excellent antimicrobial activity against Streptococci. In this work, a combinational computer approach was applied to gain insight into the structural basis and mechanism of action of sigmacidins as antimicrobials against Streptococcus pneumoniae. Both two- and three-dimensional quantitative structure-active relationships (2D and 3D QSAR) of sigmacidins displayed good predictive ability. Moreover, molecular docking and molecular dynamics simulation studies disclosed possible contacts between the inhibitors and the protein. The results obtained in this study provided understanding and new directions to the further optimizations of sigmacidins as novel antimicrobials.


  • Open Access

    Inhibition of Influenza Virus Replication by Oseltamivir Derivatives

    by Renee W. Y. Chan, Kin P. Tao, Jiqing Ye, Kevin K. Y. Lui, Xiao Yang, Cong Ma, Paul K. S. Chan

    Characterized by the high morbidity and mortality and seasonal surge, the influenza virus (IV) remains a major public health challenge. Oseltamivir is commonly used as a first-line antiviral. As a neuraminidase inhibitor, it attenuates the penetration of viruses through the mucus on the respiratory tract and inhibits the release of virus progeny from infected cells. However, over the years, oseltamivir-resistant strains have been detected in the IV surveillance programs. Therefore, new antivirals that circumvent the resistant strains would be of great importance. In this study, two novel secondary amine derivatives of oseltamivir CUHK326 (6f) and CUHK392 (10i), which bear heteroaryl groups of M2-S31 proton channel inhibitors, were designed, synthesized and subjected to biological evaluation using plaque assay. Influenza A virus (A/Oklahoma/447/2008, H1N1), influenza B viruses (B/HongKong/CUHK33261/2012), an oseltamivir-resistant influenza A virus (A/HongKong/CUHK71923/2009, H1N1) and an oseltamivir-resistant influenza B virus (B/HongKong/CUHK33280/2012) were included in the antiviral effect assessment compared to oseltamivir carboxylate (OC). Both novel compounds significantly reduced the plaque size of seasonal IV A and B, and performed similarly to OC at their corresponding half-maximal inhibitory concentration (IC50). CUHK392 (10i) functioned more effectively than CUHK326 (6f). More importantly, these compounds showed an inhibitory effect on the oseltamivir-resistant strain under 10 nM with selective index (SI) of >200.


  • Open Access

    Design, Synthesis, Biological Evaluation and In Silico Studies of Pyrazole-Based NH2-Acyl Oseltamivir Analogues as Potent Neuraminidase Inhibitors

    by Jiqing Ye, Lin Lin, Jinyi Xu, Paul Kay-Sheung Chan, Xiao Yang, Cong Ma

    Oseltamivir represents one of the most successful neuraminidase (NA) inhibitors in the current anti-influenza therapy. The 150-cavity of NA was identified as an additional binding pocket, and novel NA inhibitors have been designed to occupy the 150-cavity based on the structure information of oseltamivir carboxylate (OC) in complex with NA. In this study, a series of C-5-NH2-acyl derivatives of OC containing the pyrazole moiety were synthesized. Several derivatives exhibited substantial inhibitory activity against NA. Moreover, in silico ADME evaluation indicated that the derivatives were drug-like with higher oral absorption rates and greater cell permeability than OC. Additionally, molecular docking studies revealed that the derivatives interacted with both the NA enzyme active site and 150-cavity as expected. The results provided useful information for further structural optimization of OC.